The early spring biotech investor conference calendar continued with the annual Cowen & Co. Healthcare Conference held March 5-7, 2012 in Boston, MA. As always, my webcast notes below contain only key updates, changes, or new information, and do not represent a complete reprise of any presentation. Additional details on many of these companies can […]
Where Is Lilly In The PI3K Race?
Some 15 years ago, scientists at Eli Lilly discovered the first PI3kinase inhibitor, code name LY294002. Although only of modest potency and selectivity, it became widely used by the research community as a tool compound to elucidate the PI3K pathway. In recent years, the field has taken off with compounds in development for oncology and […]
On Eli Lilly And Innovation
Eli Lilly CEO John Lechleiter is calling for U.S. immigration officials to issue more green cards, saying a shortage of highly skilled immigrants is stifling innovation in the pharmaceutical industry. (Bloomberg) Really? Last I heard the industry has been on a firing binge, cutting back on R&D while outsourcing a multitude of functions to CROs. […]
Eli Lilly: Plenty Of Talk, Now Time For Results
Eli Lilly CEO, John Lechleiter, Ph.D., has been making the rounds lately promoting innovation in pharmaceutical research. Most recently, he delivered the keynote speech at The Economist’s 2011 Pharma Summit: Reinventing Pharma for a New Generation this past February 10, in London. In his remarks, Lechleiter highlighted some of the problems facing the innovative drug […]
Eli Lilly and the Cyclical Business of Drug Development
What people seem not to have noticed with Lilly’s acquisition of Avid Radiopharmaceuticals is the significance of the company’s diversification into the diagnostics business. Until now, Lilly had been purely involved in drug discovery. True, it has collaborations with Dx developers, in particular GE for molecular diagnostics, and Almac for a companion diagonostic to its […]
